Home World News FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or... World News FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 337 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer December 19, 2025 FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma October 27, 2022 FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... June 6, 2023 Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... July 16, 2021 Load more HOT NEWS Women Diagnosed with Early Breast Cancer Since 2000 Have About a... Oncology Research Rebounds from Pandemic Low, but Shows Cancer Patients Need... Rapid Genetic Test Could Help Guide Brain Cancer Surgery Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:...